aTyr Pharma investors may be eligible for lead plaintiff appointment.

The Gross Law Firm issued a notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding possible lead plaintiff appointment. The firm alleges that defendants made false and misleading statements about Efzofitimod's efficacy and ability to allow patients to completely taper their steroid usage. The truth emerged on September 15, 2025, when aTyr hosted an investor call announcing that patients on Efzofitimod still needed to taper their steroids. Shareholders who purchased ATYR during the class period are encouraged to contact the firm.